Literature DB >> 23710298

Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol goals in diabetics.

Wilbert S Aronow1.   

Abstract

The American Diabetes Association (ADA) 2013 guidelines state that a reasonable hemoglobin A1c goal for many nonpregnant adults with diabetes is less than 7.0% a hemoglobin A1c level of less than 6.5% may be considered in adults with short duration of diabetes, long life expectancy, and no significant cardiovascular disease if this can be achieved without significant hypoglycemia or other adverse effects of treatment. A hemoglobin A1c level less than 8.0% may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced macrovascular and microvascular complications, extensive comorbidities, and long-standing diabetes in whom the hemoglobin A1c goal is difficult to attain despite multiple glucose-lowering drugs including insulin. The ADA 2013 guidelines recommend that the systolic blood pressure in most diabetics with hypertension should be reduced to less than 140 mmHg. These guidelines also recommend use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in the treatment of hypertension in diabetics unless they are pregnant. Diabetics at high risk for cardiovascular events should have their serum low-density lipoprotein (LDL) cholesterol lowered to less than 70 mg/dL with statins. Lower-risk diabetics should have their serum LDL cholesterol reduced to less than 100 mg/dL. Combination therapy of a statin with either a fibrate or niacin has not been shown to provide additional cardiovascular benefit above statin therapy alone and is not recommended. Hypertriglyceridemia should be treated with dietary and lifestyle changes. Severe hypertriglyceridemia should be treated with drug therapy to reduce the risk of acute pancreatitis.

Entities:  

Keywords:  Blood pressure; Diabetes mellitus; Hemoglobin A1c; Lipid-lowering drugs; Serum low-density lipoprotein cholesterol; Statins

Year:  2013        PMID: 23710298      PMCID: PMC3663125          DOI: 10.4330/wjc.v5.i5.119

Source DB:  PubMed          Journal:  World J Cardiol


  18 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

Authors:  Josep Redon; Giuseppe Mancia; Peter Sleight; Helmut Schumacher; Peggy Gao; Janice Pogue; Robert Fagard; Paolo Verdecchia; Michael Weber; Michael Böhm; Bryan Williams; Khalid Yusoff; Koon Teo; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

3.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

4.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

5.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

6.  ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.

Authors:  Wilbert S Aronow; Jerome L Fleg; Carl J Pepine; Nancy T Artinian; George Bakris; Alan S Brown; Keith C Ferdinand; Mary Ann Forciea; William H Frishman; Cheryl Jaigobin; John B Kostis; Giuseppi Mancia; Suzanne Oparil; Eduardo Ortiz; Efrain Reisin; Michael W Rich; Douglas D Schocken; Michael A Weber; Deborah J Wesley
Journal:  J Am Coll Cardiol       Date:  2011-04-26       Impact factor: 24.094

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

8.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

9.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

10.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Authors:  P M Kearney; L Blackwell; R Collins; A Keech; J Simes; R Peto; J Armitage; C Baigent
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321

View more
  2 in total

1.  Cost-effectiveness of reducing glycaemic episodes through community pharmacy management of patients with type 2 diabetes mellitus.

Authors:  Delia Hendrie; Ted R Miller; Richard J Woodman; Kreshnik Hoti; Jeff Hughes
Journal:  J Prim Prev       Date:  2014-12

2.  The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice.

Authors:  Patricio Lopez-Jaramillo; Jose Lopez-Lopez; Cristina Lopez-Lopez; Miguel I Rodriguez-Alvarez
Journal:  Diabetol Metab Syndr       Date:  2014-03-04       Impact factor: 3.320

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.